Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ptc Therapeutics (PTCT) over the last 12 years, with Q3 2025 value amounting to $49.5 million.

  • Ptc Therapeutics' Accumulated Expenses rose 704.84% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year increase of 704.84%. This contributed to the annual value of $61.6 million for FY2024, which is 1691.52% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Accumulated Expenses stood at $49.5 million, which was up 704.84% from $38.2 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Accumulated Expenses high stood at $74.1 million for Q4 2023, and its period low was $24.9 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $39.4 million (2021), whereas its average is $45.2 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 5263.42% in 2023, then tumbled by 3471.28% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Accumulated Expenses (Quarter) stood at $55.7 million in 2021, then rose by 12.45% to $62.7 million in 2022, then grew by 18.26% to $74.1 million in 2023, then decreased by 16.92% to $61.6 million in 2024, then fell by 19.67% to $49.5 million in 2025.
  • Its Accumulated Expenses was $49.5 million in Q3 2025, compared to $38.2 million in Q2 2025 and $32.1 million in Q1 2025.